SEPTERNA INC

SEPN is the stock ticker for SEPterna, Inc., a clinical-stage biotechnology company focused on discovering and developing small molecule medicines targeting G protein-coupled receptors (GPCRs). The company is developing therapies for conditions such as hypoparathyroidism and other endocrine and metabolic disorders. SEPN trades on the Nasdaq Global Select Market.

The latest price of SEPN stock is displayed on this page and updates with market data. Since prices change throughout each trading session, checking the live quote is the most reliable way to see the current level. The page also shows the day's range, volume, and other near-term trading information for SEPN.

As a clinical-stage biotechnology company, SEPN can experience significant price swings when trial results, regulatory updates, or financing news are released. Volatility may also rise around data readouts or changes in the broader biotech sector. Historical price movement and recent trading ranges can be reviewed on this page for a clearer picture of SEPN's volatility.

Trading activity for SEPN varies by session. The page displays current volume, average volume, and bid-ask information, which are useful for gauging liquidity. Investors can compare SEPN's daily volume with its historical averages to assess how actively the shares change hands.

SEPterna has not been a dividend-paying company. As a clinical-stage biotech with no approved products, it has reinvested capital into research and development rather than returning cash to shareholders through dividends. Any future change to SEPN's dividend policy would be announced by the company and reflected in its public disclosures.

The primary risks for SEPN include clinical trial failures, regulatory delays, reliance on a limited pipeline, and the need for additional capital to fund research and development. Because SEPN is a clinical-stage company, it may not generate product revenue for years. Competitive pressures, intellectual property challenges, and overall biotech market sentiment can also affect the shares.